The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 7, 2022. Its latest SEC filing is a 15-12G from Mar 16, 2023.
10-Q for Q3 FY2022, filed Nov 7, 2022
The sections below describe the company as of the FY2021 annual report.
Develops an oral drug candidate to treat adults with moderate to severe alopecia areata, and licenses deuterium-modified drug candidates to pharmaceutical partners.
10-K for FY2021, filed Mar 3, 2022
Concert earns revenue from drug-candidate licenses, patent assignments and intellectual-property sales. License payments can include upfront and milestone amounts; research and development work is paid as performed, and royalties are due when licensed products sell.
10-K for FY2021, filed Mar 3, 2022The Company’s revenue is generated through collaborative licensing agreements, patent assignments and sales of intellectual property. The…View ↗
When determining whether the customer has obtained control of the goods or services, the Company considers the point at which the customer…View ↗
The Company’s revenue arrangements include payments to the Company of one or more of the following: a non-refundable, upfront payment…View ↗
To date, the Company has not recognized any royalties or sales-based milestones under its licensing and collaboration arrangements.…View ↗
$32.6M
10-K for FY2021, filed Mar 3, 2022
$32.6M ↗| Segment | Share | Revenue |
|---|---|---|
|
License and research and development revenue
|
0.1%
FY2018: 100%
|
License and research and development revenue, FY2021
$39K Sources
|
|
Other revenue
|
100% |
Other revenue, FY2021
$32.5M Sources
|
Concert works with pharmaceutical companies through licensing and development collaborations; nonprofit organizations are also named in its revenue arrangements, alongside patent assignments and intellectual-property sales.
10-K for FY2021, filed Mar 3, 2022The Company has generated revenue through arrangements with collaborators and nonprofit organizations for the development and…View ↗
In addition to our wholly-owned development programs, we have entered into collaborative arrangements with companies to develop…View ↗
The Company’s revenue is generated through collaborative licensing agreements, patent assignments and sales of intellectual property. The…View ↗
No. It lost $80.1M in FY2021.
10-Q for Q3 FY2022, filed Nov 7, 2022
−$28.9MView ↗
10-Q for Q3 FY2022, filed Nov 7, 2022
Open tableView ↗
8-K, filed Mar 6, 2023
On March 6, 2023, Concert (i) notified the Nasdaq Global Market (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq…View ↗
8-K, filed Jan 19, 2023
On January 19, 2023, Concert Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Concert”), Sun Pharmaceutical Industries…View ↗
Shrank. Revenue fell 77% in 4 years, from $143.9M in FY2017 to $32.6M in FY2021, about 31% a year.
Competes with Eli Lilly and and Pfizer
10-K for FY2021, filed Mar 3, 2022We are developing CTP-543 as an oral agent for the treatment of moderate to severe alopecia areata. If CTP-543 receives marketing approval…View ↗
Loading...
